FILE PHOTO: A Takeda logo is seen in its research hub in Cambridge, Massachusetts, U.S., November 26, 2018. REUTERS/Julie Steenhuysen
BEIJING: Bullish on China’s innovation-driven biopharmaceutical environment, Takeda Pharmaceutical Co vows to further enlarge its investment in China, a top official of the Japanese drugmaker said.
Takeda plans to raise its revenue growth in emerging markets to account for one-fifth of its projected total by fiscal year 2031, up from the current roughly 13%, said Ricardo Marek, president of Takeda’s growth and emerging markets business unit.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
